A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life.

[1]  D. Rice,et al.  Estimating the cost of illness. , 1967, American journal of public health and the nation's health.

[2]  Rice Dp,et al.  Estimating the cost of illness. , 1967 .

[3]  A Gafni,et al.  The standard gamble method: what is being measured and how it is interpreted. , 1994, Health services research.

[4]  M J Buxton,et al.  Evaluating patient-based outcome measures for use in clinical trials. , 1998, Health technology assessment.

[5]  A. Benson,et al.  Recommended guidelines for the treatment of chemotherapy-induced diarrhea. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Zacker,et al.  The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. , 2000, The oncologist.

[7]  A. Benson,et al.  Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. , 2000, Journal of pain and symptom management.

[8]  D. Cope.  Management of chemotherapy-induced diarrhea and constipation. , 2001, The Nursing clinics of North America.

[9]  David McDaid,et al.  Searching Literature Databases for Health Care Economic Evaluations: How Systematic Can We Afford to Be? , 2002, Medical care.

[10]  L. Saltz.  Understanding and managing chemotherapy-induced diarrhea. , 2003, The journal of supportive oncology.

[11]  L. Elting,et al.  The economic burden of supportive care of cancer patients , 2004, Supportive Care in Cancer.

[12]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Viele.  Overview of chemotherapy-induced diarrhea. , 2003, Seminars in oncology nursing.

[14]  A. Shah,et al.  Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis , 2005, Supportive Care in Cancer.

[15]  R. Haynes,et al.  Optimal search strategies for detecting health services research studies in MEDLINE , 2004, Canadian Medical Association Journal.

[16]  J. Ajani,et al.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Gabrail,et al.  Clinical implications of chemotherapy-induced diarrhea in patients with cancer. , 2005, The journal of supportive oncology.

[18]  A. Shah,et al.  Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[19]  R Brian Haynes,et al.  Optimal search strategies for detecting cost and economic studies in EMBASE , 2006, BMC Health Services Research.

[20]  G. Warsi,et al.  A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. , 2006, The journal of supportive oncology.

[21]  G. Dranitsaris,et al.  Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea , 2007, Current oncology.

[22]  R. Dobish,et al.  Chemotherapy induced diarrhea , 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[23]  M. Stafford,et al.  Health state utilities for non small cell lung cancer , 2008, Health and quality of life outcomes.

[24]  A. Argiris,et al.  Evaluating the supportive care costs of severe radiochemotherapy‐induced mucositis and pharyngitis , 2008, Cancer.

[25]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[26]  R. Hegazi,et al.  Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. , 2009, JPEN. Journal of parenteral and enteral nutrition.

[27]  A. Stringer,et al.  Chemotherapy-induced diarrhoea is associated with a modified microbiome in cancer patients , 2009 .

[28]  A. Levy,et al.  Societal preference values for advanced melanoma health states in the United Kingdom and Australia , 2009, British Journal of Cancer.

[29]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[30]  W. Voigt,et al.  Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management , 2010, Therapeutic advances in medical oncology.

[31]  J. Ajani,et al.  Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. , 2010, Journal of the National Cancer Institute.

[32]  K. Beusterien,et al.  Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study , 2010, Health and quality of life outcomes.

[33]  M. Trudeau,et al.  Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer , 2010, Current oncology.

[34]  M. Groenvold,et al.  Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily , 2011, Leukemia & lymphoma.

[35]  H. Aarstad,et al.  Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. , 2011, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[36]  A. Hauschild,et al.  Health-related Quality of Life Before and During Adjuvant Interferon-&agr; Treatment for Patients With Malignant Melanoma (DeCOG-Trial) , 2011, Journal of immunotherapy.

[37]  J. Giesinger,et al.  Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract , 2012, BMC Cancer.

[38]  G. Dranitsaris,et al.  Preference weights for chemotherapy side effects from the perspective of women with breast cancer , 2013, Breast Cancer Research and Treatment.

[39]  A. Spira,et al.  Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial , 2013, Investigational New Drugs.

[40]  L. Sequist,et al.  Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Wilsgaard,et al.  Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors , 2013, Acta oncologica.

[42]  T. Conroy,et al.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Katherine Payne,et al.  A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events , 2013, PharmacoEconomics.

[44]  M. Beckmann,et al.  Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group , 2013, Breast Cancer Research and Treatment.

[45]  Richard Sullivan,et al.  Economic burden of cancer across the European Union: a population-based cost analysis. , 2013, The Lancet. Oncology.

[46]  K. Yanaga,et al.  Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life , 2013, World Journal of Surgical Oncology.

[47]  W. A. van der Kloot,et al.  Illness Perceptions and Quality of Life in Japanese and Dutch Women with Breast Cancer , 2013, Journal of psychosocial oncology.